Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in China Region
Target Company Name:
Country:
Advisory:
Sector:
Partner:
Country:
Advisory:
Sector:
Partner:
Under the terms of the agreement, ApolloBio will make an upfront payment of $16 million to Tocagen, plus potential payments of $4 million in near-term development milestones
Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in China Region
Advisor to the buyer